harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Both Indiana University and Memorial Sloan Kettering Cancer Center (MSKCC) have published their series’ of salvage high-dose ...

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

One treatment, or infusion, is sometimes called a “round.” Most neoadjuvant chemotherapy regimens are given intravenously. After a chemotherapy infusion, you have a rest period to allow your ...

Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...

"This new regimen highlights the importance of combining dual-targeted therapy with chemotherapy to improve patient outcomes in the first-line setting, and the durable responses are a significant ...

Unlike conventional high-dose chemotherapy regimens, MC uses low-dose agents like cyclophosphamide and etoposide, often in combination with non-chemotherapeutic agents such as celecoxib and ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase ...

as well as resistance to standard chemotherapy regimens. Kopetz noted that preclinical data showed there was a benefit in combining encorafenib, cetuximab, and cytotoxic chemotherapy, and that ...